Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.04)
# 2,863
Out of 5,182 analysts
44
Total ratings
45%
Success rate
-7.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $20 → $18 | $9.41 | +91.29% | 1 | Apr 1, 2026 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $12 → $7 | $0.93 | +652.45% | 5 | Apr 1, 2026 | |
| DMRA Damora Therapeutics | Initiates: Outperform | $46 | $25.36 | +81.39% | 1 | Mar 25, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $101 → $126 | $96.53 | +30.53% | 5 | Mar 4, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $206.60 | +10.36% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $17.39 | +107.02% | 1 | Dec 15, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $35.20 | +175.57% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $24.50 | +63.27% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $28.19 | +130.58% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $783.50 | +16.15% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.55 | +222.58% | 1 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $2.94 | +104.08% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $21.49 | +691.07% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.76 | +320.17% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $266.04 | -22.57% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $4.41 | +398.87% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.92 | +242.47% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $128.79 | -53.41% | 1 | Oct 5, 2022 |
MeiraGTx Holdings
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $18
Current: $9.41
Upside: +91.29%
Jasper Therapeutics
Apr 1, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $0.93
Upside: +652.45%
Damora Therapeutics
Mar 25, 2026
Initiates: Outperform
Price Target: $46
Current: $25.36
Upside: +81.39%
Mirum Pharmaceuticals
Mar 4, 2026
Maintains: Outperform
Price Target: $101 → $126
Current: $96.53
Upside: +30.53%
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $206.60
Upside: +10.36%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $17.39
Upside: +107.02%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $35.20
Upside: +175.57%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $24.50
Upside: +63.27%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $28.19
Upside: +130.58%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $783.50
Upside: +16.15%
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.55
Upside: +222.58%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.94
Upside: +104.08%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $21.49
Upside: +691.07%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.76
Upside: +320.17%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $266.04
Upside: -22.57%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $4.41
Upside: +398.87%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.92
Upside: +242.47%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $128.79
Upside: -53.41%